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Objective: The objective of this systematic review was to assess cell/biomaterial treatments of degen-
erative disc disease in controlled animal trails. The primary endpoints were restoration of disc height and
T2 signal intensity.
Method: PubMed, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and
Cochrane Database of Systematic Reviews (CDSR) were searched for studies reporting on the use of tissue
engineering treatments (cells/biomaterials/cells and biomaterials) for degenerative disc disease treat-
ments in a controlled trial. Publication bias was assessed graphically using funnel plots and Egger’s
regression. Data were grouped by follow-up duration e early (<4 weeks), intermediate (4e12 weeks)
and late (>12 weeks), and weighted mean differences (WMD) were calculated using DerSimonianeLaird
Random Effect models.
Results: Thirteen papers, published between 2004 and 2011, were included in this study. In comparison
with the injured disc, all three treatments showed a positive effect in disc height, but none of the
treatments restored disc height compared to the healthy disc. Overall, there seemed to be a better effect
on disc height restoration for the treatment with cells and biomaterials. None of the treatments could
achieve the same T2 signal intensity as the healthy disc, and compared to the injured disc, only the
treatment with cells and biomaterials showed consistently better results.
Conclusion: Treatment of an injured/degenerating disc with cells, cells plus biomaterial or biomaterial
alone has a potential for at least a partial regeneration of the disc. However, so far, none of the treatments
is able to effectively restore the properties of a healthy disc.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Rationale
Low back pain is a frequent condition with a global lifetime
prevalence of up to 80%1. While most patients recover from an
acute episodewithin 10weeks, approximately 10% of patients show
transition to chronic low back pain2. Given the high prevalence of
the acute disease, the incidence of chronic low back pain is
tremendous, creating annual health care costs of 20 billion USD in: P. Vavken, Department of
vard Medical School, Boston,
.edu (P. Vavken).
s Research Society International. Pthe United States3. Degeneration of the vertebral discs is believed to
play a key role in the development of chronic low back pain. With
aging, the cell density within the nucleus pulposus (NP) of the disc
decreases4,5 resulting in a decline in the production of important
extracellular matrix (ECM) proteins such as type 2 collagen6 and
aggrecans7 with the latter being the back bone of proteoglycans.
Particularly, the loss of hydrophilic proteoglycans within the NP
reduces the disc’s height and compressibility and thus its load
distributing and shock absorbing capacity. Hence, biomechanical
stress is increased on the adjacent annulus ﬁbrosus and interver-
tebral articulations leading to annular tears, disc herniation and
spondyloarthropathy. Calciﬁcation of the cartilagenous vertebral
endplates seems to play a pivotal role in disc degeneration8. With
this process, the endplates become less permeable for oxygen and
nutrient supplies9. As a result, the metabolism of cells residing in
the central parts of the disc is jeopardized.ublished by Elsevier Ltd. All rights reserved.
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degeneration involve a variety of non-operative modalities such as
physical therapy10, anti-inﬂammatory medication11 and steroid
injections12. For those who fail these conservative measures,
surgical measures come into play. Current treatment options range
from partial discectomy to spinal fusion, disc arthroplasty and
dynamic stabilization techniques. However, discectomy and fusion
techniques have been shown to accelerate degeneration at the level
of the disc13 and in the adjacent segments14 respectively. In addi-
tion, these operations are associated with considerable complica-
tion rates. Joint arthroplasty and non-fusion techniques may spare
motion, but cannot restore normal spine biomechanics. Hence,
their long term beneﬁt remains currently unclear15.
The limitations of current treatment options may call for
a paradigm shift in the treatment of degenerative disc disease
(DDD) from late to early interventions in the pathologic cascade.
This could be achieved by measures that restore the cellular
anatomy and ECM production within the disc before irreversible
structural changes are established. On a macroscopic level, this
approach could also restore disc height. Previous research tried to
reach this goal in many different ways. Injection or gene-based
delivery of growth factors (BMPs) directly into the NP has been
suggested by various authors16e18. Current research focuses on cell
based-approaches applying the principles of tissue engineering. In
these approaches, autologous NP cells19,20 or bone marrow derived
mesenchymal stem cells (MSCs)21e23 are harvested, expanded
in vitro and delivered into the NP. The in vitro expansion of cells can
also be coupled with seeding of cells on- or into a biomaterial to
create a tissue engineered cell scaffold construct24,25. Alternatively,
biomaterials without cells can be used to restore disc anatomy.
Such biomaterials are composed of various types of polymers that
can be injected and are also capable of inducing proliferation of
residing disc cells26,27.
Although the number of animal studies evaluating cell-based
and biomaterial based strategies to treat DDD is currently
increasing, their overall capabilities and relative effectiveness in
improving tissue quality and restoring disc height are still unclear,
which has been a major burden in the translation of such tech-
niques from animal models into human applications.
Objectives
The objectives of this systematic reviewwere to accrue evidence
for the effectiveness of cell/biomaterial treatments of DDD in
controlled animal trails. The primary endpoints of interest were
restoration of disc height and improvement of tissue quality as
measured by T2 signal intensity on MRI. Additionally, histological
and immunohistochemical assessmentwas included as a secondary,
descriptive endpoint.
Materials and methods
We conducted this systematic review in accordance to the
PRISMA (Preferred Reporting Items for Systematic reviews and
Meta-Analyses) statement, the established guideline for systematic
reviews put forth by the CONSORT group (www.consort-statement.
org)24,28.
Eligibility criteria
Studies were included if they reported on the use of tissue
engineering treatments (cells/biomaterials/cells and biomaterials)
for degenerative disc disease treatments in a controlled trial. All
types of treatments were admitted, but there had to be a defect or
injury model. Studies on tissue engineering use in healthy discswere not eligible, neither were longitudinal or cohort studies, or
abstracts without full text articles. There was no limitation for
follow-up duration.
Data sources
The databases PubMed, Cumulative Index to Nursing and Allied
Health Literature (CINAHL), EMBASE, Cochrane Central Register of
Controlled Trials (CENTRAL), and Cochrane Database of Systematic
Reviews (CDSR) were searched online. All dates and languages
were included. The last search was performed on July 31th, 2011.
Search strategy
The search algorithm was “(degenerative disc disease OR
intervertebral disc) AND (cell OR biomaterial) AND animal
model”, using these terms as keywords and exploded MeSH terms.
All searches were unlimited to language and publication date. In
addition, the bibliographies of the included studies were reviewed
by hand to identify additional relevant studies.
Study selection
Eligibility of studies was assessed independently and in dupli-
cate and crosschecked to avoid errors. Disagreement was resolved
by discussion or, if necessary, with the help of the senior author.
Title and abstracts from all search results were screened for eligi-
bility in duplicate. Studies were excluded if title and/or abstract
clearly invalidated eligibility. Full text articles were obtained for all
studies matching the inclusion criteria or with unclear eligibility.
Data collection process
All data were extracted in duplicate and entered into a pre-
deﬁned datasheet. After extraction, data consistency was checked
by a third investigator. Disagreement was resolved by consensus.
Data items
We extracted data on the study design characteristics for
descriptive purposes. The main endpoint was radiographic
evidence of treatment success as deﬁned by (1) restoration of disc
height and (2) tissue quality, as shown by signal intensity on T2-
weighted MRI images29. Both restoration of disc height and T2
signal intensity are important clinical parameters in the evaluation
of disc disease, since they reﬂect the pathomechanism of disc aging
and degeneration. The healthy intervertebral disc is rich in
proteoglycans, which are strong attractors of water, thus creating
a swelling pressure that maintains disc height and elasticity. The T2
signal intensity can, inexpensively and easily, be used to evaluate
disc hydration. As the disc ages and degenerates it looses proteo-
glycan content, which, in turn results in water losses and thus
reduced disc height and low T2 signal intensity. Numerical
outcomes that were reported in more than one study and with
methodological consistency (same scales, same scores, etc) were
extracted for data synthesis. In cases of overlapping data, studies
were merged as far as possible; completely overlapping studies
were excluded. As a secondary endpoint, we included histological
and immunohistochemical assessments.
Data synthesis
Publication bias among the included studies was assessed
graphically using funnel plots and mathematically using Egger’s
weighted regression30. The presence of between-study
A. Mehrkens et al. / Osteoarthritis and Cartilage 20 (2012) 1316e13251318heterogeneity was qualiﬁed by Cochrane’s Q test, using a P-value of
10% to adjust for the low power of this test in small samples, and
quantiﬁed using the I2 index17.
Data were grouped by follow-up duration e early (up to 4
weeks), intermediate (up to 12 weeks) and late (more than 12
weeks) e and by type of treatment e cells only vs. cells and
biomaterial vs. biomaterial only. Two control groups e healthy
discs and untreated defects e were compared individually against
treated discs. To pool data, weighted mean differences (WMD)
and standardized mean differences (SMD) were calculated, i.e.,
the differences in means between the experimental and the
control group. SMD and can be categorized as small (SMD < 0.3),
medium (<0.5) or large (>0.8). Regardless of size, any of these
values can be statistically signiﬁcant or not, i.e., statistical
signiﬁcance does not automatically imply clinical meaning31. In
the face of statistical heterogeneity, DerSimonianeLaird Random
Effect models were used. All calculations were performed using
Intercooled STATA 12 (StataCorp LP, College Station, TX, USA).
The level of signiﬁcance for pooled estimates was set at 5%.
Results
Study selection
Our search produced 741 papers in total. One hundred and forty
two publications were obtained and reviewed based on the criteria
described above. One additional paper was identiﬁed by biblio-
graphic cross-reference. Two foreign language papers could not be
obtained. Thirteen papers, published between 2004 and 2011 in
English, were included in this study (Flow chart).
Characteristics of the included studies
Among the 13 included papers, three papers offer data on the
use of biomaterials alone, six papers present data on cells alone,
and four on the use of cells with biomaterials (Table I).
Most authors used bone marrow stem/stromal cells (BMSC) as
a cell source, predominantly autologous21,28,30,32e35 whereas one
groupusedhumanBMSC in a ratmodel36. That samegroupused also
human adipose-tissue-derived stromal cell (ADSC) as a cell source31.
Twogroups implantedNP cells: Iwaschima et al. usedhuman cells in
a rabbit model37, Ruan et al. used autologous NP cells in a canine
model38. When cells were combined with a biomaterial, four
different scaffoldswere used: twogroupsused atelocollagengel21,37,
one group used a PLGA Scaffold38 and Yang et al. created a construct
of rabbit BMSC and ﬁbrinous gelatin-transforming growth factor-b1
(PFG-TGF-b1)35. Polyglycolic acid (PGA)39 and platelet-rich plasma-
impregnated gelatin hydrogel microspheres (PRP-GHMs)40 were
implanted without cells.Table I
Characteristics of the interventions in the included studies
Author Year Journal Biomaterial Cells
Abbushi 2008 Spine PGA None
Crevensten 2004 Ann Biomed Eng None MSC
Hiyama 2008 J Orthop Res None BM-MSC
Iwashina 2006 Spine Atelocollagen Human NP
Jeong 2009 Cytotchnology None BM-MSC
Jeong 2010 Acta Neurochir None ADSC
Miyamoto 2010 Arthiritis Res & Therapy None Synovial M
RuanA 2010 Tissue Eng A PLGA None
RuanB 2010 Tissue Eng A PLGA NP
Sakai 2006 Biomaterials Atelocollagen BM-MSC
Serigano 2010 J Orthop Res None BM-MSC
Yang 2010 Spine Fibrin&TGF-b BM-MSC
Sawamura 2009 Tissue Eng A PRP-gelatin NoneCells with and without biomaterials
In 2004, Crevensten et al.32 injected MSC from rat bone marrow
marked with CM-DiI membrane stain into rat coccygeal discs using
hyaluronan gel as a carrier. The total number of injected cells into
the disc as well as the percentage of viable injected cells in the NP
was measured at day 0,7,14 and 28. Disc heights were measured
with X-ray in a customized setup directly before implantation and
thereafter at the same timepoints as the cell measurements.
Sakai et al. (2006)21 transplanted autologous MSCs from bone
marrow into a rabbit model of disc degeneration to determine if
stem cells could repair degenerated intervertebral discs (IVD). LacZ
expressing MSCs were embedded in atelocollagen gel and trans-
planted into rabbit IVDs 2 weeks after induction of degeneration.
Changes in disc height by plain radiograph, T2-weighted signal
intensity in MRI, histology, immunohistochemistry and matrix
associated gene expressions were evaluated between normal
controls (NC) without operations, sham operated with only disc
degeneration being induced, and MSC-transplanted animals at 2, 4,
8, 16 and 24 weeks after transplantation.
Iwashina et al. (2006)37 transplanted cells of a human nucleus
pulposus cell (NPC) line embedded in atelocollagen into a rabbit
disc degeneration model. Disc height (plain X-ray), macroscopic
appearance, histological ﬁndings, immunohistochemistry and
several gene expression levels were measured and the presence of
a possible graft-vs.-host reaction was assessed by immunohisto-
chemistry for CD4 and CD58 at several different timepoints over
a period of 26 weeks.
The study of Hiyama et al. (2008)30 used measurements of the
Fas-ligand (FasL) to evaluate whether MSC-transplantation has an
effect on the suppression of disc degeneration and preservation of
immune privilege in a canine model of disc degeneration. Mature
beagles were separated into a NC group, anMSC group, and the disc
degeneration (nucleotomy-only) group. In the MSC group, 4 weeks
after nucleotomy, MSCs were transplanted into the degeneration-
induced discs. Radiological imaging (standard X-ray as well as T2-
weighted signal intensity by MRI) was performed at 0, 2, 4, 8 and
12 weeks, immunohistochemical and RT-PCR analyses for FasL as
well as histological and biochemical analyses were performed after
12 weeks.
Composite constructs of poly (L-lactic-co-glycolic acid) (PLGA)
scaffoldeNPCs using tissue engineering methods were used by
Ruan et al. (2010)38 in a canine model. NP cells were isolated
from the lumbar intervertebral discs of a beagle dog. NP cells were
cultured, expanded in vitro, and seeded onto a three-dimensional
porous PLGA scaffold. The composite was tested in beagle dogs in
three groups of nucleotomy alone, nucleotomy with PLGA
implantation and nucleotomy with PLGA scaffold/NP cells
composite implantation. Radiographic evaluation was performed
pre- and 4, 8 and 12 weeks post-operatively: Disc height andAnimal model nExp nCo (nucleotomized) nNml (healthy)
Lapine 6 6 0
Murine 8 8 0
Canine 6 6 6
Lapine 8 8 8
Murine 8 8 8
Murine 20 20 20
SC Lapine 6 6 6
Canine 6 6 0
Canine 6 6 0
Lapine 10 10 10
Canine 6 6 6
Lapine 18 18 18
Lapine 32 32 32
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the hydration status of the NP was determined using T2-weighted
MRI. Biomechanical and immunohistochemical analysis were done
4, 8, and 12 weeks post-operatively.
Yang et al. (2010)41 used a rabbit model to evaluate the effect of
transplantation of a composite of MSCs with ﬁbrinous gelatin-
transforming growth factor-b1 (PFG-TGF-b1) on the disc height
index (DHI). The annulus ﬁbrosus was punctured and the NP tissue
from the intervertebral discs was aspirated. The degenerative disc
model was produced in each rabbit, which were then divided into
three groups: degenerative model; PFG-TGF-b1 transplanted group
and MSC-PFG-TGF-b1 transplanted group. Radiologic (standard X-
ray as well as T2-weighted signal intensity byMRI), histological and
immunohistochemistry evaluations were performed at 4, 8, and 12
weeks.
Jeong et al. contributed two studies to the ﬁeld31,36. In their work
of 2009, they used a rat coccygeal model to investigate the effects of
transplanting human MSCs and to examine MSC survival in
degenerative discs. Implantations were performed at 2 weeks post-
injury. Radiologic (standard X-ray as well as T2-weighted signal
intensity by MRI), histological and immunohistochemistry evalua-
tions were performed at 2, 4, 6, and 8 weeks post-injury.
In 2010, the same group investigated the potential of human
ADSC implantation to restore disc in a rat IVD model. The ﬁrst
coccygeal disc segments of a SpragueeDawley rat was left undam-
aged as a control group and two other segments were damaged by
needle injection. Twoweeks later, ADSCs or salinewere injected into
each of the two damaged segments. Radiologic (disc height as well
as disc signal intensity was measured with MRI) and histological
ﬁndings were recorded at 2, 4, 6 and 8 weeks post-injury.
In the same year, Miyamoto et al. (2010)33 published their work
on intradiscal transplantation of synovial MSCs after aspiration ofFig. 1. Shows a forest plot for disc height restoration as measured by DHI. The tested interv
columns on the right show the outcome as WMD(with 95% conﬁdence interval) in DHI for th
each study has in the pooled WMD (last row). The center of the ﬁgure shows a graphic repr
95% CI-bar crosses the vertical black line of WMD ¼ 0, then there is no statistically signiﬁ
entirely to the left or right of the “0” line, then there is signiﬁcant effect in favor of tissue eng
control group (left). The pooled effect of all studies is given as the blue diamond at the boNP in rabbits. The NP tissues of rabbit’s intervertebral discs were
aspirated to induce disc degeneration, and allogenic synovial MSCs
were transplanted. Imaging analyses (standard X-ray as well as T2-
weighted signal intensity by MRI) and histological analysis were
done 2, 4, 6, 8, 16, 24 weeks post-operatively. In addition, human
synovial MSCs and rat NP cells were co-cultured, and species
speciﬁc microarray were performed to investigate interaction
between synovial MSCs and NP cells.
In another study in 2010, Serigano et al.34 conducted an in vivo
study using a canine disc degeneration model to determine the
optimal amount of donor MSC for maximum beneﬁt. Autologous
MSCs were transplanted into degenerative discs at 105, 106, or 107
cells per disc. Radiographic evaluation was performed at day 0 as
well as at 4 (timepoint of MSC-transplantation), 8, 12 and 16 weeks.
Histology, apoptotic cells counts and measurements of viability of
NP-cells and survival of transplanted green ﬂuorescent protein-
positive (GFP-positive) MSCs were done after 16 weeks.
Most recently, Feng et al. (2011)28 compared transplanted MSCs
with nucleus pulposus cells (NPCs) in a degenerative disc model in
rabbits. Healthy animals without surgery and sham-operated
animals in which only disc degeneration was induced acted as
control. Changes in disc height, according to plain radiography
were evaluated initially and every 2 weeks thereafter, T2-weighted
signal intensity on MR imaging, histology, sulfated glycosamino-
glycan (sGAG)/DNA and associated gene expression levels, were
evaluated after 16-weeks.
Biomaterial alone
Abbushi et al. (2008)39 evaluated the capacity of a cell free
implant of PGA which was immersed in allogenic serum in a rabbit
model. Implants were evaluated 1 week and 6 months after the
operation. Outcome parameters were DHI and T2-weighted signalention was the treatment of nucleotomized discs with cells and biomaterials. The two
e individual studies, as well as the weight, as a function of the variance of the estimate,
esentation of the numerical outcomes, i.e., plots of the 95% CIs as horizontal bars. If the
cant difference between the two groups assessed in the respective study. If the bar is
ineered treatment with cells and biomaterials (right) or in favor of the nucleotomized,
ttom of the graph, with the same rules applying.
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and magnetic resonance imaging. Finally, discs were explanted and
investigated histologically.
Sawamura et al. (2009)40 characterized the in vivo effects of
platelet-rich plasma-impregnated gelatin hydrogel microspheres
(PRP-GHMs) treatment in a degenerated IVD rabbit model. 2, 4 and
8 weeks after implantation, the spinal columns were removed “en
bloc” andmade available for MRI evaluation (T1 and T2), RT-PCR for
gene expression in the NPs, immunohistochemistry (to identify
proliferating and apoptotic cells) as well as kinetic analysis of TGF-
b release in IVDs to examine the efﬁcacy of GHMs as a release
matrix for PRP growth factors.
Finally, the 2010 poly (L-lactic-co-glycolic acid) (PLGA)
scaffoldenucleus pulposus (NP) cells study by Ruan et al.38 as well
as the 2004 hyaluraonic acid and BM-MSC study by Crevensten
et al.32 (both described above) also offered data on “biomaterials
only” groups.
Restoration of disc height
There was some evidence for publication bias among the studies
presenting disc height (P ¼ 0.070). However, the subgroup analysis
showed that this heterogeneity occurred only during the early
follow-up (P ¼ 0.002), with no evidence for publication bias at theFig. 2. Shows a forest plot for disc height restoration as measured by DHI, change in h
nucleotomized discs with cells only. A signiﬁcant effect of cells on disc height can be seenintermediate (P ¼ 0.545) or late (P ¼ 0.076) follow-ups. There was
evidence for signiﬁcant statistical heterogeneity among groups
comparing tissue engineering treatments with healthy discs or
untreated discs (both P < 0.05).
Even though there seemed to be some improvement of disc
height over time for the treatment with cells combined with
biomaterial (Fig. 1) and cells alone (Fig. 2), none of the treatments
was able to achieve restoration of disc height compared to the
healthy, untreated disc (Table II). The use of biomaterials alone did
not show a sufﬁcient restoration of disc height (Fig. 3).
In comparison with the untreated, injured disc, all three treat-
ments were able to show a positive effect in disc height, gradually
improving over time (Table II).
Overall, there seemed to be a better effect on restoration of disc
height for the treatment with cells and biomaterials as compared to
the other two treatments.
T2 signal intensity
There was no evidence for publication bias among the studies
presenting T2 signal intensity as an outcome (P ¼ 0.292). However,
there was evidence for signiﬁcant statistical heterogeneity among
groups comparing tissue engineering treatments with healthy discs
or untreated discs (both P < 0.1).eight in percent, and change in mm. The tested intervention was the treatment of
for DHI, change in percent, and change in mm.
Table II
Effect size for restoration of disc height
Type of treatment Timepoint of follow-up
Early Intermediate Late
Compared to nucleotomized discs
Cells 1.6** 2.3*** 1.4 (n.s.)
Cells & Biomaterial 1.7** 3.4** 4.2*
Biomaterial 1.5*** 2.6 (n.s.) 3.6***
Overall 1.5*** 2.7*** 2.9*
Compared to healthy discs
Cells 3.4*** 3.8*** 2.4***
Cells & Biomaterial 2.0*** 1.5 (n.s.) 0.9 (n.s.)
Biomaterial 2.8*** n.a. n.a.
Overall 2.8*** 3.2*** 1.6 (n.s.)
n.s. not signiﬁcant, *(P < 0.05), **(P < 0.01), ***(P < 0.001)).
Flow chart.
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as the normal, healthy disc. Only the treatment with cells and
biomaterial could be evaluated at all three points in time: There
seemed to be a slight improvement at the intermediate timepoint,
followedbydeteriorationof the signal at the late timepoint (Table III).
When compared to the untreated, injured disc, only the treat-
ment with cells and biomaterials showed constantly better results.
As opposed to the comparison with the normal, healthy disc, there
was a continuous improvement over time. Treatment with cells
alone could only show a better result at the early timepoint with
deterioration thereafter (even though statistically not signiﬁcant),
treatment with biomaterial only improved from inferior results at
the early (not signiﬁcant) and intermediate timepoints to a favor-
able result in the late control (Table III).
Histology and immunohistochemistry
Most of the authors included histology and immunohisto-
chemistry in their follow-up and documented, for example, cellFig. 3. Shows a forest plot for disc height restoration as measured by DHI, change in height in percent, and change in mm. The tested intervention was the treatment of
nucleotomized discs with a biomaterial only. A signiﬁcant effect of cells on disc height can be seen for DHI and change in mm. But not change in percent since the 95% CI contains
the value zero for the pooled WMD.
Table III
Effect size for T2 signal intensity
Type of treatment Timepoint of follow-up
Early Intermediate Late
Compared to nucleotomized discs
Cells 0.8** 0.8 (n.s.) 0.4 (n.s.)
Cells & Biomaterial 3.3*** 5.1*** 6.8***
Biomaterial 1.6 (n.s.) 1.4*** 4***
Overall 0.2 (n.s.) 1 (n.s.) 3.4 (n.s.)
Compared to healthy discs
Cells n.a. 0.8 (n.s.) 5.7***
Cells & Biomaterial 3.8*** 1.6** 2.5***
Biomaterial 7.3 (n.s.) n.a. n.a.
Overall 4.9*** 1.1 (n.s.) 4*
n.s. not signiﬁcant, *(P < 0.05), **(P < 0.01), ***(P < 0.001)).
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and collagen type II as well as RT-PCR for aggrecan, versican and
collagen type II. When compared to the injured, untreated control
group, all authors could demonstrate better results in the treated
group. However, none of the treated groups regained the properties
of the untreated, healthy disc on a histological level (Table IV).
Discussion
Summary of evidence
Themain objective of this systematic reviewwas to evaluate the
effectiveness of a tissue engineered approach in the treatment of
DDD in controlled animal studies in general. The primary endpointsTable IV
Summary of ﬁndings from histology and immunohistochemistry
Author Year Therapy Treated discs as compared to normal, healthy discs:
Cell survival Degenerative
Changes*
S-O
Crevensten 2004 cb 100% at 28 weeks n.a. n.a.
b
Sakai 2006 cb 72% at 8 weeks 1e2 Sim
Iwashima 2006 c 89% in NP at 24 weeks 2e3 Sim
Hiyama 2008 c n.a. 1e3 Sim
Ruan 2010 cb n.a. n.a. n.a.
b n.a. n.a. n.a.
Yang 2010 cb Apoptosis:
16% at 12 weeks
n.a. n.a.
b Apoptosis: 22%
at 12 weeks
n.a. n.a.
Jeong 2009 c n.a. 1e2 n.a.
Jeong 2010 c n.a. n.a. n.a.
Miyamoto 2010 c Present, not quantiﬁed Looked similar,
not graded
n.a.
Serrigano 2010 c 91e94% at 12 weeks 1e2 n.a.
Feng 2011 c n.a. Some Less
c n.a. Some Less
Abbushi 2008 b n.a. n.a. n.a.
Sawamura 2009 b Apoptosis: 17% at 8 weeks n.a. n.a.
* If applicable according to grading system by Nishimura K, Mochida J. (Spine, 1998
together.of interest were restoration of disc height and improvement of
tissue quality as measured by T2 signal intensity on MRI. Addi-
tionally, histological and immunohistochemical assessment was
included as a secondary, descriptive endpoint. As a second objec-
tive, we assessed if there were differences among the three
described techniques (cells, cells and biomaterial, biomaterial) in
achieving the aforementioned endpoints and therefore, if one
approach may seem to be a more promising candidate than the
others for further studies in the treatment of DDD.
Overall, none of the treatments could restore the properties of
the healthy disc. However, when compared to the untreated,
degenerated disc, all treatments showed an improvement in disc-
height and/or signal intensity as well as in the histological/immu-
nohistochemical ﬁndings over time. This indicates, depending on
the treatment, regenerative potential in the degenerating or
already degenerated disc.
In detail, the included studies showed different, individual
approaches in trying to treat DDD by implanting cells (autologous/
homologous/xenologous), cells plus biomaterial or biomaterial
alone.
Among these three different groups, the treatment consisting of
cells combined with biomaterial seemed to be the more effective
than the other two. As discussed earlier, the degeneration of the
disc includes cell death and subsequent loss of ECM. The superior
outcome of the hybrid construct over each component alone may
be due to the fact that these constructs immediately provide
a microenvironment that is able to, at least partially, mimic the
native viscoelastic properties as well as the cell function and
homeostasis of the NP which may facilitate the regenerative
process overall.Comments
PG Type II collagen
n.a. n.a. At day 28, the number of cells was about
the same as at day 0. Viability of the cells
was at 100%, most of the cells were located
within the NP.
ilar Similar n.a.
ilar Similar Similar
ilar Similar n.a. FasL-positive cells increased following
MSC-transplantation at 12 weeks after
the ﬁrst operation, compared to nucleotomy
only, to approximate the level found in the
NC group.
FasL mRNA was restored in the MSC-
transplanted group when compared
with the nucleotomy group.
n.a. Similar
n.a. n.a.
n.a. Grayscale value:
148.11  1.93 at
12 weeks
n.a. Grayscale value:
152.37  2.85 at
12 weeks
n.a. n.a.
n.a. Present
n.a. Higher
n.a. Similar
n.a. n.a.
n.a. n.a.
n.a. n.a. Histologic evaluation was not quantiﬁed.
n.a. n.a.
); n.a.: not described/quantiﬁed; c: cells; b: biomaterial; cb: cells and biomaterial
A. Mehrkens et al. / Osteoarthritis and Cartilage 20 (2012) 1316e1325 1323By looking at each of the three different groups individually, we
did not ﬁnd relevant (i.e., signiﬁcant) differences in outcomewithin
each group. This lack of signiﬁcance may be explained by the
paucity of studies in the ﬁeld that met our inclusion criteria. Within
the 11 studies with cells, the cells came from four different species
(rat, rabbit, dog and human) and within the same species the cells
were harvested from different tissue (bonemarrow, NP and adipose
tissue). The different species as well as the tissue may each have
their own, slightly different effect on restoration of the disc. A
similar argumentation accounts for the scaffolds used and even
more so for the combination of cells and scaffold. Therefore, with
the data that we evaluated, we are not able to favor one cell source,
one biomaterial or a combination of both over another.
Limitations
Like any systematic review, the validity of our ﬁndings is affected
by the availability and quality of primary data. In this case, only 13
primary studies were available. A recent study in the Journal of Bone
and Joint Surgery (American Volume) reported that orthopedic
systematic reviewspublishedbetween1984and1999pooled amean
of 43 studies (range 2e130)41. We refrained from doing a formal
analysis of the quality of the included studies41, because in animal
studies typical quality indicators such as randomization or double
blinding do not apply in the sameway as they do in human research.
We only present data of animal models, which always raises the
question of how the results will be applicable in humans. As in
many other ﬁelds of research, one has to carefully choose the
appropriate animal model for disc research42. Clearly this might
affect the translational value of our ﬁndings.
The results of the reviewed animal models may have only
limited value for a human application.
As a part of the NP, notochordal cells play an important role as
they inﬂuence proliferation and regeneration in the intervertebral
disc43e45. Most authors agree that unlike in the NP of rats, rabbits
and non-chondrodystrophic dogs, notochordal cells are usually not
present in the adult NP of humans or chondrodystrophic dogs such
as beagles42,46. As for the presented review, one has to consider two
aspects: On the one hand, this review compares data of rats, rabbits
and beagles (chondrodystrophic dogs) which may raise the ques-
tion, if the presence of notochordal cells (or not) would inﬂuence
the results. By comparing the data of the rats and rabbits with the
beagles, we didn’t ﬁnd any signiﬁcant differences.
On the other hand, the results from the beagles may be more
applicable to humans, since the NP of the beagle is potentially more
similar to the human than the NP of species whose discs do not
naturally degenerate46 which would be in favor of translating the
results to a human model.
However, recently Risbud et al. hypothesized in their review
about the role of notochordal cells that in all animals, including
human, the NP retains notochordal cells throughout life47.
In conclusion, the reviewed models are nevertheless very useful
at this stage since they are able to provide us with preliminary data
under streamlined, highly controlled and reproducible conditions.
Another limitation of the presented data may be the relatively
short follow-up. Only three authors presented results of 24
weeks22,33 or more37. Even though the treated groups demonstrate
a gradual improvement of T2 signal intensity and disc-height over
time, one can only speculate about the possible long term effects of
the applied therapy.
Conclusion
On the level of animal studies, treatment of an injured/degen-
erating disc with cells, cells plus biomaterial or biomaterial alonehas a potential for at least a partial regeneration of the disc.
However, so far, none of the treatments is able to effectively restore
the properties of a healthy disc.
The data of our review favor the approach of a combined
treatment with cells and biomaterial. Therefore, in times of
increasingly limited resources, we propose that further studies on
a cell based approach should concentrate on “hybrid-solutions” of
cells combined with biomaterial.
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